Literature DB >> 2076489

Electrophysiological and arrhythmogenic effects of platelet activating factor during normal perfusion, myocardial ischaemia and reperfusion in the guinea-pig.

N A Flores1, D J Sheridan.   

Abstract

1. Platelet activating factor (PAF) is often used to study the effects of platelet activation. While direct myocardial electrophysiological effects of PAF have been described in superfused myocardial tissue, little is known about its actions on the whole heart. 2. The cellular electrophysiological and arrhythmogenic effects of PAF (10(-11)M, 10(-10)M and 10(-9)M) were studied during normal perfusion, global myocardial ischaemia and reperfusion in Langendorff-perfused guinea-pig hearts at 32 degrees C. 3. PAF (10(-9)M) increased the incidence of ventricular fibrillation during ischaemia and reduced action potential duration (APD) during normal perfusion and early myocardial ischaemia (10(-9)M and 10(-10)M). PAF also reduced refractory period (RP) during normal perfusion (10(-9)M) and early ischaemia (10(-9)M and 10(-10)M). PAF prevented recovery of APD (10(-9)M) and RP (10(-9)M and 10(-10)M) during reperfusion. PAF at a concentration of 10(-11)M had no electrophysiological effects. 4. PAF (10(-9)M) increased the QRS width of the electrocardiogram during late ischaemia while 10(-10)M PAF raised pacing threshold during late ischaemia. 5. Perfusion pressure was increased, and developed tension decreased by 10(-9)M PAF. 6. These results demonstrate that PAF has direct myocardial electrophysiological effects in the whole heart which occur during normal perfusion and are capable of augmenting the effects of myocardial ischaemia, but are independent of the presence of platelets.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076489      PMCID: PMC1917725          DOI: 10.1111/j.1476-5381.1990.tb14149.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  A microcomputer system for real-time analysis of cardiac action potentials.

Authors:  D J Sheridan; A J Bell; W J Penny; W Culling
Journal:  J Med Eng Technol       Date:  1983 Sep-Oct

2.  Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs.

Authors:  P Bessin; J Bonnet; D Apffel; C Soulard; L Desgroux; I Pelas; J Benveniste
Journal:  Eur J Pharmacol       Date:  1983-01-21       Impact factor: 4.432

3.  Arrhythmias and cellular electrophysiological changes during myocardial "ischaemia" and reperfusion.

Authors:  W J Penny; D J Sheridan
Journal:  Cardiovasc Res       Date:  1983-06       Impact factor: 10.787

4.  Human neutrophil-derived platelet activating factor.

Authors:  G Z Lotner; J M Lynch; S J Betz; P M Henson
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

5.  Sheep platelets as a model for human platelets: evidence for specific PAF (platelet activating factor) receptors.

Authors:  C W Slattery; D O Beaumont
Journal:  Thromb Res       Date:  1989-09-01       Impact factor: 3.944

6.  Effect of platelet-activating factor on coronary circulation of the domestic pig.

Authors:  G Feuerstein; L M Boyd; D Ezra; R E Goldstein
Journal:  Am J Physiol       Date:  1984-03

7.  Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig.

Authors:  R Levi; J A Burke; Z G Guo; Y Hattori; C M Hoppens; L M McManus; D J Hanahan; R N Pinckard
Journal:  Circ Res       Date:  1984-02       Impact factor: 17.367

8.  Platelet function studies in coronary artery disease. V. Evidence for enhanced platelet microthrombus formation activity in acute myocardial infarction.

Authors:  P Mehta; J Mehta
Journal:  Am J Cardiol       Date:  1979-04       Impact factor: 2.778

9.  The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations.

Authors:  J Benveniste; C Boullet; C Brink; C Labat
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

10.  Human platelet stimulation by acetyl glyceryl ether phosphorylcholine.

Authors:  L M McManus; D J Hanahan; R N Pinckard
Journal:  J Clin Invest       Date:  1981-03       Impact factor: 14.808

View more
  6 in total

1.  Effects of the PAF antagonists BN50726 and BN50739 on arrhythmogenesis and extent of necrosis during myocardial ischaemia/reperfusion in rabbits.

Authors:  S Chakrabarty; D S Fluck; N A Flores; D J Sheridan
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

Review 2.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

3.  Nupafant, a PAF-antagonist prototype for suppression of ventricular fibrillation without liability for QT prolongation?

Authors:  K E Baker; L M Wood; M Whittaker; M J Curtis
Journal:  Br J Pharmacol       Date:  2006-08-21       Impact factor: 8.739

4.  Ability to induce atrial fibrillation in the peri-operative period is associated with phosphorylation-dependent inhibition of TWIK protein-related acid-sensitive potassium channel 1 (TASK-1).

Authors:  Erin Harleton; Alessandra Besana; George M Comas; Peter Danilo; Tove S Rosen; Michael Argenziano; Michael R Rosen; Richard B Robinson; Steven J Feinmark
Journal:  J Biol Chem       Date:  2012-12-10       Impact factor: 5.157

5.  Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous "mediators" facilitated by interactions, and moderated by paradoxical antagonism.

Authors:  Kathryn E Baker; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2004-04-05       Impact factor: 8.739

6.  Platelets and cardiac arrhythmia.

Authors:  Jonas S S G de Jong; Lukas R C Dekker
Journal:  Front Physiol       Date:  2010-12-30       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.